MedTrace Logo

A Pilot Study of Glioma Associated Antigen Vaccines in Conjunction with Poly-ICLC in Pediatric Gliomas

NCT01130077 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2024-12-06

No results posted yet for this study

Summary

The overall objective of this pilot study is to collect immunological and safety data following administration of vaccinations with HLA-A2. This data will be used to decide whether a larger study of clinical efficacy is warranted.

Conditions

  • Newly Diagnosed Pediatric Pontine Glioma
  • Newly Diagnosed Pediatric High Grade Glioma
  • Recurrent Pediatric High Grade Glioma
  • Recurrent Pediatric Low Grade Glioma

Interventions

BIOLOGICAL

HLA-A2 restricted glioma antigen peptides vaccine

Vaccine given every 3 weeks

BIOLOGICAL

Poly-ICLC

Vaccine given every 3 weeks

Sponsors & Collaborators

  • Ellie Kavalieros Fund

    collaborator UNKNOWN

  • Translational Brain Tumor Research Fund

    collaborator UNKNOWN

  • Connor's Cure

    collaborator OTHER

  • James Felker

    lead OTHER

Principal Investigators

  • James Felker, MD · University of Pittsburgh

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
12 Months
Max Age
21 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-02-28
Primary Completion
2024-11-01
Completion
2024-11-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01130077 on ClinicalTrials.gov